Primary biliary cholangitis (PBC) is an autoimmune disease that causes the destruction of bile ducts within the liver. The loss of bile ducts results in bile acid buildup, which causes ...

PBC is the most frequent CD-related liver disease, being regarded as the most prevalent autoimmune disorder detected in CD after Hashimoto thyroiditis, Type 1 diabetes mellitus and Sjogren syndrome.

Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not appropriately diagnosed and treated. "PBC is one of those liver diseases ...

At present, the gold standard for the diagnosis of recurrent PBC is a liver biopsy demonstrating the characteristic histologic features, with the exclusion of other entities that can lead to graft ...

GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...

and how to monitor liver health. Researchers note that people with ulcerative colitis may have an increased risk of developing primary sclerosing cholangitis and primary biliary cirrhosis than ...

There isn’t a cure for PBC, but the right treatment plan can slow its progress and boost your quality of life as you live with it.

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

PBC is more common in women and causes liver damage that can progress to liver failure, particularly if left untreated. The most common symptoms of PBC are pruritus (chronic itch) and fatigue ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat patients with the rare liver disease primary biliary cholangitis (PBC). The ...